StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Non-GAAP Selling, General & Administrative Expense by Quarter

Non-GAAP Selling, General & Administrative Expense ($M) ($M)

Amgen Non-GAAP Selling, General & Administrative Expense: $1,717M in Q2 2026, up 4.1% from a year earlier.

Latest, Q2 2026
1,717
Period ended Jun 30, 2026
Change on a year earlier
+4.1%
1,650 in Q2 2025
History
36 quarters
Since Q3 2017
Sources
32
Documents cited below

Where the Q2 2026 figure comes from

“|| Non-GAAP selling, general and administrative expenses | $ | 1,717 | $ | 1,650 | $ | 3,300 | $ | 3,305”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP Selling, General & Administrative Expense ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,717+4.1%Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20261,583-4.4%Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 20251,937+6.5%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 20251,700+8.6%Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 20251,650-2.1%Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 20251,655-3.3%Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 20241,819+3.1%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 20241,565+21.0%Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20241,686+36.3%Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 20241,712+39.9%Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 20231,764+20.2%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 20231,293+1.3%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 20231,237-5.8%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 20231,224+0.9%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 20221,468+2.4%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 20221,276+1.3%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗

Breakdown

What makes up non-GAAP Selling, General & Administrative Expense

Cite this data

StockData. (2026). Amgen Non-GAAP Selling, General & Administrative Expense ($M), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/ng-sga

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.